ArticleMedicine2025
Discussion on the mechanism of Bao-Yuan Yang-Xin Decoction in treating coronary heart disease based on network pharmacology and molecular docking.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to explore the potential therapeutic mechanisms of the Bao-Yuan Yang-Xin Decoction (BYXD) in the treatment of coronary heart disease (CHD) by integrating network pharmacology with the specificity of molecular docking methods. Effective components and their potential targets of BYXD were screened from the Traditional Chinese Medicine Systems Pharmacology and BATMAN-Traditional Chinese Medicine databases. Targets related to CHD were confirmed through the GeneCards database. A "drug-component-target" network was created using Cytoscape, and a protein-protein interaction network was established with STRING. Finally, biological enrichment analysis of the targets was performed using the Database for Annotation, Visualization and Integrated Discovery, and the top 20 highly enriched Kyoto Encyclopedia of Genes and Genomes pathways were further investigated. The pivotal active constituents of BYXD are identified as stigmasterol, quercetin, β-sitosterol, luteolin, and baicalein in this study. Major targets include PTGS2, PTGS1, NCOA2, ADRB2, SCN5A, RXRA, NCOA1, ESR1, AR, and DPP4. BYXD conveys its healing properties to CHD by controlling key communication pathways, including advanced glycation end products-receptor, tumor necrosis factor, HIF-1, and IL-17. Molecular docking shows a high degree of binding affinity between stigmasterol and PTGS2, while β-sitosterol demonstrates a notable affinity for NCOA1. The probable mechanisms underlying BYXD's efficacy in CHD treatment are disclosed by applying network pharmacology and molecular docking. The integral components of BYXD are identified to selectively engage with a range of critical targets, modulating the associated signaling pathways that are pivotal in the pathophysiology of CHD. Such targeted modulation provides a substantive scientific basis for the clinical application of BYXD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.